Intercept Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	2017 - 2013
Revenue	317.68	285.71	260.75	233.97	252	179.8	Upgrade
Revenue Growth (YoY)	14.64%	9.57%	11.45%	-7.16%	40.15%	37.30%	Upgrade
Cost of Revenue	0.63	0.98	1.21	2.35	4.21	2.52	Upgrade
Gross Profit	317.05	284.73	259.55	231.62	247.79	177.29	Upgrade
Selling, General & Admin	211.73	176.3	177.49	260.5	317.42	255.47	Upgrade
Research & Development	160.42	176.64	182.75	189.03	242.8	207.3	Upgrade
Other Operating Expenses	6.26	0	-0.28	11.81	0	0	Upgrade
Operating Expenses	378.41	352.94	359.95	461.34	560.22	462.78	Upgrade
Operating Income	-61.36	-68.22	-100.41	-229.73	-312.43	-285.49	Upgrade
Interest Expense / Income	10.23	21.39	54.42	48.05	41.14	30.52	Upgrade
Other Expense / Income	-9.97	-311.42	-63.4	-2.9	-8.89	-6.77	Upgrade
Pretax Income	-61.61	221.82	-91.43	-274.88	-344.68	-309.24	Upgrade
Net Income	-61.61	221.82	-91.43	-274.88	-344.68	-309.24	Upgrade
Shares Outstanding (Basic)	42	34	32	33	32	28	Upgrade
Shares Outstanding (Diluted)	42	34	32	33	32	28	Upgrade
Shares Change	21.87%	6.09%	-3.26%	4.16%	11.21%	13.61%	Upgrade
EPS (Basic)	-2.18	6.56	-2.87	-8.34	-10.89	-10.86	Upgrade
EPS (Diluted)	-2.18	6.56	-2.87	-8.34	-10.89	-10.86	Upgrade
Free Cash Flow	-62.83	-27.35	-41.46	-175.76	-237.75	-240.88	Upgrade
Free Cash Flow Per Share	-1.50	-0.81	-1.30	-5.33	-7.51	-8.46	Upgrade
Gross Margin	99.80%	99.66%	99.54%	98.99%	98.33%	98.60%	Upgrade
Operating Margin	-19.31%	-23.88%	-38.51%	-98.19%	-123.98%	-158.78%	Upgrade
Profit Margin	-19.39%	77.64%	-35.06%	-117.49%	-136.78%	-171.99%	Upgrade
Free Cash Flow Margin	-19.78%	-9.57%	-15.90%	-75.12%	-94.34%	-133.97%	Upgrade
EBITDA	-50.77	245.46	-29.48	-218.61	-294.49	-274.14	Upgrade
EBITDA Margin	-15.98%	85.91%	-11.31%	-93.44%	-116.86%	-152.46%	Upgrade
Depreciation & Amortization	0.61	2.26	7.53	8.21	9.05	4.58	Upgrade
EBIT	-51.38	243.2	-37.01	-226.83	-303.54	-278.72	Upgrade
EBIT Margin	-16.17%	85.12%	-14.19%	-96.95%	-120.45%	-155.01%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).